Targeted Therapeutics Research Award
Funded equally by LUNGevity Foundation and the American Lung Association
Michael P. Lisanti, MD, PhD
Thomas Jefferson University
Philadelphia
PA
Genes that can suppress the development of tumors are often lost or silenced during the development of human lung tumors. Because they function as a “brake” that normally prevents the onset of lung tumors, they provide new targets for the development of replacement therapies for the effective treatment of lung cancers. Dr. Lisanti is testing the effectiveness of the replacement of a novel tumor suppressor gene, caveolin-1.